Deakin home > Deakin University Library > Deakin Research Online > Intracellular drug delivery by sulfatide-mediated liposomes to gliomas

Intracellular drug delivery by sulfatide-mediated liposomes to gliomas

Shao, Ke, Hou, Qingsong, Duan, Wei, Go, Mei Lin, Wong, Kim Ping and Li, Qiu-Tian 2006, Intracellular drug delivery by sulfatide-mediated liposomes to gliomas, Journal of controlled release, vol. 115, no. 2, pp. 150-157.

Attached Files (Some files may be inaccessible until you login with your Deakin Research Online credentials)
Name Description MIMEType Size Downloads

Title Intracellular drug delivery by sulfatide-mediated liposomes to gliomas
Author(s) Shao, Ke
Hou, Qingsong
Duan, Wei
Go, Mei Lin
Wong, Kim Ping
Li, Qiu-Tian
Journal name Journal of controlled release
Volume number 115
Issue number 2
Start page 150
End page 157
Publisher Elsevier B.V.
Place of publication Amsterdam, The Netherlands
Publication date 2006-10-10
ISSN 0168-3659
Keyword(s) intracellular drug delivery
liposomes
sulfatide
gliomas
doxorubicin
Summary We described here a liposomal carrier system in which the targeting ligand was sulfatide, a glycosphingolipid known to bind several extracellular matrix (ECM) glycoproteins whose expression was highly up-regulated in many tumors. In vitro experiments with human glioma cell lines demonstrated that robust intracellular uptake of the liposomes depended specifically on the presence of sulfatide as the key liposomal component. Significant amount of the liposomes remained largely intact in the cytoplasm for hours following their internalization. When anticancer drug doxorubicin (DOX) was encapsulated in such liposomes, most of the drug was preferably delivered into the cell nuclei to exert its cytotoxicity. Use of this drug delivery system to deliver DOX for treatment of tumor-bearing nude mice displayed much improved therapeutic effects over the free drug or the drug carried by polyethylene glycol (PEG)-grafted liposomes. Our results demonstrate a close link between effective intracellular uptake of the drug delivery system and its therapeutic outcome. Moreover, the sulfatide-containing liposomes (SCL) may represent an interesting ligand-targeted drug carrier for a wide spectrum of cancers in which sulfatide-binding ECM glycoproteins are expressed.
Language eng
Field of Research 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2006, Elsevier B.V.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30009152

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in Deakin Research Online is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 13 times in TR Web of Science
Scopus Citation Count Cited 14 times in Scopus
Access Statistics: 428 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 13 Oct 2008, 15:52:39 EST